RECOR Medical & Otsuka v. Medtronic Ireland: Federal Circuit Vacates & Remands
RECOR Medical and Otsuka Medical Devices challenged Medtronic Ireland at the Federal Circuit over US8845629B2, a patent covering ultrasound-based thermally-induced renal neuromodulation devices. After 597 days, the court vacated the lower decision and remanded — nullifying the ruling below without resolving the underlying infringement question on the merits.
Federal Circuit nullifies lower ruling in renal neuromodulation patent dispute
RECOR Medical, Inc. and its co-plaintiff Otsuka Medical Devices Co., Ltd. filed this Federal Circuit appeal on 8 August 2023 against Medtronic Ireland Manufacturing Unlimited Co., asserting rights under US8845629B2 — a patent directed at ultrasound apparatuses for thermally-induced renal neuromodulation. The patent covers technology designed to reduce blood pressure by targeting renal sympathetic nerves using focused ultrasound energy, a clinically significant area in the treatment of hypertension.
On 27 March 2025, the Federal Circuit issued an order vacating the decision below and remanding the case. A vacatur at the appellate level means the lower tribunal’s ruling carries no legal force going forward — it is as though that decision was never entered. The case now returns to the lower forum, which must reconsider the matter in a manner consistent with the Federal Circuit’s guidance, leaving the infringement question unresolved at this stage.
The 597-day duration of the appeal suggests the Federal Circuit engaged with substantive legal or procedural issues before reaching its vacatur order, though the public record does not detail the specific grounds. Vacatur and remand — rather than outright reversal — typically signals the appellate court identified error or an incomplete record below without itself resolving the underlying dispute. The ultimate outcome of the infringement action remains open pending the remand proceedings.
Filing to Vacated and Remanded in 597 days
597 days — longer than the median Federal Circuit appeal cycle of ~12–18 months
Federal Circuit vacates: what the remand means for both parties
Vacatur nullifies the lower decision entirely
When the Federal Circuit vacates a lower decision, it erases that ruling’s legal effect — neither party can rely on it as precedent or a final determination. Unlike a reversal (which substitutes a new outcome), vacatur returns the matter to the lower forum to proceed anew, typically with specific instructions. This preserves the appellate court’s role without requiring it to adjudicate the underlying infringement merits directly.
Lower decision has no further legal forceRECOR & Otsuka get a second chance on the merits
For RECOR Medical and Otsuka, vacatur is a meaningful procedural win. Any adverse findings from the lower proceeding are wiped from the record, allowing them to re-litigate the infringement or validity questions on remand without the weight of an unfavourable prior ruling. The enforceability of US8845629B2 remains live and the patent has not been invalidated by these proceedings.
Patent survives; infringement claim revivedMedtronic loses the protection of the lower ruling
Medtronic Ireland had the benefit of whatever determination the lower tribunal reached in its favour. Vacatur strips that protection entirely. On remand, the case restarts under the Federal Circuit’s corrective instructions, meaning Medtronic must re-engage on the substantive patent dispute without the procedural shelter of the now-nullified decision. Litigation risk and cost exposure re-open.
Lower ruling no longer shields MedtronicUltrasound renal neuromodulation IP landscape stays contested
The vacatur and remand extends uncertainty over US8845629B2 across the thermally-induced renal neuromodulation sector. Competitors developing catheter-based or ultrasound-based hypertension devices should treat this patent as actively enforced. The Federal Circuit’s willingness to engage and vacate — rather than simply affirm — suggests the underlying legal questions are non-trivial and may set important claim-scope precedent once the remand concludes.
IP uncertainty persists in renal denervation marketFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | RECOR MEDICAL, INC. | Company | Medical device company — holder of US8845629B2 covering renal neuromodulation ultrasound techSearch in Eureka ↗ |
| Co-Plaintiff | Otsuka Medical Devices Co., Ltd. | Company | Search in Eureka ↗ |
| Defendant | MEDTRONIC IRELAND MANUFACTURING UNLIMITED CO. | Company | Irish manufacturing subsidiary of Medtronic plc — global medical device multinationalSearch in Eureka ↗ |
| Plaintiff counsel | Ashley M. Fry | Attorney | Counsel for RECOR MEDICAL, INC.Search in Eureka ↗ |
| Plaintiff counsel | Ashley N. Finger | Attorney | Counsel for RECOR MEDICAL, INC.Search in Eureka ↗ |
| Plaintiff counsel | Gabriel K. Bell | Attorney | Counsel for RECOR MEDICAL, INC.Search in Eureka ↗ |
| Plaintiff counsel | Matthew J. Moore | Attorney | Counsel for RECOR MEDICAL, INC.Search in Eureka ↗ |
| Plaintiff counsel | Roger J. Chin | Attorney | Counsel for RECOR MEDICAL, INC.Search in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins, LLP | Law Firm | Representing RECOR MEDICAL, INC.Search in Eureka ↗ |
| Defendant counsel | Allen S. Cross | Attorney | Counsel for MEDTRONIC IRELAND MANUFACTURING UNLIMITED CO.Search in Eureka ↗ |
| Defendant counsel | Douglas HallwardDriemeier | Attorney | Counsel for MEDTRONIC IRELAND MANUFACTURING UNLIMITED CO.Search in Eureka ↗ |
| Defendant counsel | James Lawrence Davis | Attorney | Counsel for MEDTRONIC IRELAND MANUFACTURING UNLIMITED CO.Search in Eureka ↗ |
| Defendant law firm | Ropes & Gray, LLP | Law Firm | Representing MEDTRONIC IRELAND MANUFACTURING UNLIMITED CO.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘VACATED AND REMANDED’ — carries significant procedural weight. Vacatur at the appellate level annuls the lower tribunal’s decision in its entirety, removing it from the legal record. The court applies a deferential standard to most lower-court findings but will vacate where it identifies reversible legal error, an incomplete record, or an intervening change in law. The remand instruction signals the Federal Circuit declined to resolve the underlying dispute itself, instead directing the lower forum to reconsider under corrected legal standards. The infringement question over US8845629B2 therefore remains open.
US8845629B2 — Ultrasound Apparatuses for Thermally-Induced Renal Neuromodulation
US8845629B2, filed under application number US12/754337, protects ultrasound apparatus technology for achieving thermally-induced renal neuromodulation — the targeted disruption of renal sympathetic nerve activity to reduce hypertension. The patent sits within a technically specialised domain: focused ultrasound energy is directed at the renal nerves surrounding the renal artery, inducing thermal effects that modulate sympathetic signalling without surgical intervention. This approach is differentiated from radiofrequency-based renal denervation by its use of acoustic energy delivery.
The renal denervation market has attracted major medtech players including Medtronic, SoniVive (formerly RECOR Medical’s parent), and ReCor’s Paradise system. US8845629B2 represents foundational IP in the ultrasound-based segment of that market. With the Federal Circuit actively engaged via vacatur-and-remand, the patent’s claim boundaries remain commercially contested. Any device developer pursuing ultrasound-mediated renal sympathetic neuromodulation — whether via intravascular or extracorporeal delivery — must treat this patent as an active enforcement risk.
Should you run an FTO analysis against US8845629B2?
If your R&D pipeline includes any apparatus that uses focused or high-intensity ultrasound to thermally modulate renal sympathetic nerves — whether catheter-based, intravascular, or extracorporeal — US8845629B2 is a live freedom-to-operate concern. This is not a resolved case: the Federal Circuit’s vacatur means the infringement question will be re-litigated. RECOR Medical and Otsuka have demonstrated a willingness to pursue enforcement through appellate courts, and the patent has not been invalidated.
PatSnap Eureka’s FTO Search Agent can map your device’s feature set against the claim language of US8845629B2, surface prior art relevant to validity, and identify design-around opportunities before the remand proceedings produce a potentially binding claim-construction ruling. Running this analysis now — before the lower court issues revised findings — gives product teams the maximum window to adapt. Search US8845629B2 in Eureka to begin your clearance analysis.
Run a freedom-to-operate analysis on US8845629B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in ultrasound and renal neuromodulation IP
Cases involving ultrasound-based medical device patents appealed to the Federal Circuit, including renal denervation and neuromodulation infringement actions.
What this case signals for the renal neuromodulation IP landscape
Vacatur at the Federal Circuit keeps US8845629B2 in active play — with potentially broader claim-scope implications on remand.
Vacatur extends the litigation lifecycle — budget for remand proceedings
This case did not end at the Federal Circuit. Vacatur and remand means the underlying infringement dispute returns to the lower forum. Companies with products in the renal neuromodulation space should anticipate further litigation activity around US8845629B2 and plan IP strategy accordingly.
US8845629B2 remains enforceable — FTO analysis is still urgent
The patent has not been invalidated or disclaimed. Any device using focused ultrasound to thermally modulate renal sympathetic nerves sits in the risk zone. The Federal Circuit’s intervention signals the patent holder is committed to enforcement, making freedom-to-operate analysis a commercial priority for device developers in this space.
RECOR v MEDTRONIC — key questions answered
The Federal Circuit vacated the lower tribunal’s decision entirely and remanded the case. This means the lower ruling has no legal effect. The infringement question over US8845629B2 — covering ultrasound renal neuromodulation apparatuses — must be reconsidered by the lower forum under the Federal Circuit’s corrective guidance. The patent has not been invalidated.
US8845629B2 (application US12/754337) protects ultrasound apparatuses for thermally-induced renal neuromodulation — devices that use focused ultrasound energy to thermally disrupt renal sympathetic nerve activity, targeting hypertension without surgical intervention. The patent is central to the RECOR Medical Paradise ultrasound renal denervation system.
Plaintiffs-appellants are RECOR Medical, Inc. and Otsuka Medical Devices Co., Ltd., represented by Latham & Watkins LLP. The defendant-appellee is Medtronic Ireland Manufacturing Unlimited Co., an Irish manufacturing entity within the Medtronic group, represented by Ropes & Gray LLP.
A reversal substitutes a new outcome for the lower court’s decision — the appellate court decides the matter itself. A vacatur nullifies the lower decision without substituting a new ruling, instead returning the case to the lower forum (remand) to reconsider under corrected legal standards. Vacatur typically signals the appellate court found error but declined to resolve the underlying dispute itself.
The vacatur does not invalidate US8845629B2. The patent remains in force and the infringement claim is live pending remand. The vacatur affects only the lower tribunal’s prior ruling — not the patent’s validity or RECOR Medical and Otsuka’s right to enforce it. Parties in the renal neuromodulation device market should treat this patent as an active enforcement risk.
PatSnap Eureka searches patents and litigation data to answer instantly.